Open AccessOx-LDL suppresses PMA-induced MMP-9 expression and activity through CD36-mediated activation of PPAR-γ
Author(s) -
Kyung Jin Lee,
Hyun A Kim,
Pyeung Hyeun Kim,
Han Soo Lee,
Kyung Ran,
Jeong Hyun Park,
Dae Joong Kim,
Jang Hee Hahn
Publication year - 2004
Publication title -
experimental and molecular medicine/experimental and molecular medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.703
H-Index - 82
eISSN - 2092-6413
pISSN - 1226-3613
DOI - 10.1038/emm.2004.68
Subject(s) - ciglitazone , cd36 , troglitazone , peroxisome proliferator activated receptor , u937 cell , chemistry , activator (genetics) , receptor , matrix metalloproteinase , endocrinology , medicine , biology , apoptosis , biochemistry
During chronic inflammatory response, mono- cytes/macrophages produce 92-kDa matrix metalloproteinase-9 (MMP-9), which may contribute to their extravasation, migration and tissue remodeling. Activation of peroxisome proliferator- activated factor receptor-g (PPAR-g) has been shown to inhibit MMP-9 activity. To evaluate whether ox-LDL, a PPAR-g activator, inhibits PMA-induced MMP-9 expression and activity, and if so, whether CD36 and PPAR-g are involved in this process, we investigated the effect of ox-LDL on MMP-9 expression and activity in PMA-activated human monocytic cell line U937. PMA-induced MMP-9 expression and activity were suppressed by the treatment with ox-LDL (50 mg/ml) or PPAR-g activators such as troglitazone (5 mM), ciglitazone (5 mM), and 15d- PGJ2 (1 mM) for 24 h. This ox-LDL or PPAR-g activator-mediated inhibition of MMP-9 activity was diminished by the pre-treatment of cells with a blocking antibody to CD36, or PGF2a (0.3 mM), which is a PPAR-g inhibitor, as well as overexpression of a dominant-negative form of CD36. Taken together, these results suggest that ox-LDL suppresses PMA-induced MMP-9 expression and activity through CD36-mediated activation of PPAR-g.